Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 7/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517503 | 0.94 | ALOX5AP (0.42) | ADRB2STAT3MDM2PARP1ACACB | |
| SCHEMBL6519844 | 0.94 | ALOX5AP (0.42) | ADRB2STAT3MDM2PARP1ACACB | |
| SCHEMBL6519504 | 0.92 | PARP1 (0.45) | ADRB2STAT3PARP1PRKAA2CHRM4 | |
| SCHEMBL6524325 | 0.91 | CHRM2 (0.41) | ADRB2STAT3MDM2PARP1RORC | |
| SCHEMBL6524323 | 0.91 | CHRM2 (0.41) | ADRB2STAT3MDM2PARP1RORC | |
| SCHEMBL3711560 | 0.91 | PARP1 (0.41) | ADRB2STAT3PARP1PRKAA2CHRM4 | |
| SCHEMBL3659359 | 0.90 | STAT3 (0.43) | ADRB2STAT3PARP1PRKAA2HIF1A | |
| SCHEMBL3659855 | 0.89 | STAT3 (0.45) | ADRB2STAT3PRKAA2 | |
| SCHEMBL12788268 | 0.89 | CHRM4 (0.43) | STAT3MDM2PARP1CHRM4 | |
| SCHEMBL6520829 | 0.89 | STAT3 (0.42) | ADRB2STAT3PARP1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| WO-2009050522-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | GPR119, GIPR, GPR39 | ADRB2 126/4885STAT3 1637/4885MDM2 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.